Delivering on the promise of cell therapy

Our lead product is designed to allow for controlled, sustained delivery of mesenchymal stem cell (MSC) secreted factors. This approach immobilizes the MSCs in an extracorporeal device, allowing for doses of therapeutic secreted factors that are unattainable by direct injection.

Mr. Miller has over 18 years of experience in the life science industry. Mr. Miller has previously held the roles of Executive Director and Head, Corporate Development at FORMA Therapeutics, a clinical stage oncology company, and Head of Business Development – Asia Pacific for Quosa, Inc., a life science informatics company. He began his biotech career at Eli Lilly and Company, where he led the identification, evaluation, and in-licensing of research informatics technologies in the Global External Research & Development group. Brian received BA degrees in Chemistry and Business from Goshen College, an MS degree in Health Sciences from the Harvard-MIT Division of Health Sciences Technology, and an MBA from the MIT Sloan School of Management.

Dr. Parekkadan is an Assistant Professor of Bioengineering at Massachusetts General Hospital and is an affiliated faculty member of the Harvard Stem Cell Institute and the Broad Institute.In 2012, he was recognized by Harvard Medical School with a Young Mentor of the Year Award and by the White House with a Presidential Early Career Award for Scientists and Engineers (PECASE), the highest honor given by the US government for early career investigators. His doctoral research generated the IP behind the formation of the company, and he leads the R&D of Sentien.He received a B.S. in Biomedical Engineering from Rutgers University (2003) and a Ph.D. in Chemical and Medical Engineering from the Harvard-MIT Division of Health Sciences and Technology (2008).

Dr. Deans is currently the Chief Scientific Officer of Rubius Therapeutics. He has more than 25 years of experience in adult stem cell therapeutics which includes work with stem cells from bone marrow including both hematopoietic as well as mesenchymal stem cell populations. He has previously served as the executive vice president at Athersys, Inc., vice president of research at Osiris Therapeutics, and director of research and development at Baxter Healthcare.

Dr. Heidecker joined the Boehringer Ingelheim Venture Fund in 2010 to invest in early innovative therapeutic life science companies. In October 2013, Martin established the US-office of BIVF in Cambridge, MA, where he is focusing on biotech seed-investments. He has 15 years of investing and commercial experience in both venture capital and global pharma companies. In addition to Sentien, he serves as board member of AMP Therapeutics in Leipzig, ArmaGen in Calabasas and 121bio in Cambridge.

Mr. Ganz has been active in the healthcare industry for over 30 years.He is currently principal of RGA Life Sciences, a life science consultancy based out of Wilmette, IL.Formerly, Mr. Ganz was Chief Operating Officer of Piramal Critical Care, a global pharmaceutical company headquartered in Bethlehem, PA, President and Chief Executive Officer at Omnisonics Medical Technologies, President of the North American Renal Division for Baxter International, Inc., and a Divisional VP and General Manager of Vascular Products at Abbott Laboratories.

Dr. Fruehauf is the Co-Founder and General Partner of BioInnovation Capital. He is also a founder of LabCentral, a launchpad for high-potential biotech startups, and serves as its president and executive director. Prior to LabCentral, he founded Cambridge Biolabs, a contract research facility serving startup and virtual companies in Kendall Square. Dr. Fruehauf is also a co-founder of ViThera Pharmaceuticals, Deltix and Cequent Pharmaceuticals, and an advisor or board member to numerous life sciences companies and non-profits.

Giacomo currently serves both as Managing Partner at Chiesi Ventures and the Head of Global Corporate Development at the Chiesi Group.

In his tenure with the Chiesi Group he has directly structured and executed deals with $2B in value ranging from sell-side to buy-side M&A, in- and out-licensing, and spin-outs. In 2014, he founded Chiesi Ventures as a joint venture with Pappas Capital.

Before going back to the Chiesi Group, Giacomo was a consultant with Bain & Co, where he led teams in a variety of assignments including due diligence, restructuring and strategy projects for consumer goods and IT companies in different countries. Previously he was with Accenture where he led large teams in outsourcing projects across Europe and US for clients in the transportation and retail business.

Giacomo earned a M.Sc. degree Magna cum Laude in Telecommunications Engineering from the University of Parma, Italy, and an MBA from the University of Chicago Booth School of Business with concentrations in Entrepreneurship and Finance. He currently serves as a Board Member or Observer on the Board of Chiesi, Chiesi USA, Aura Bioscience, Minoryx Therapeutics, Glycomine, Sentien Biotech and Palladio Biosciences. He also sits on the Advisory Board of Abingworth Capital Partners and Mercurio Capital Partners.

Dr. Littman is President of Translational Medicine Associates, LLC, an independent consulting company serving customers in the areas of translational research, early clinical development planning and execution, risk assessment for early biotech and biomarker development. Previously, he spent 19 years at Pfizer, culminating in his role as Vice President and Global Head of Translational Medicine, and he is board certified in Internal Medicine and Rheumatology.

Dr. Lin is Director of Translational Research in the division of Nephrology at Massachusetts General Hospital.He is board certified in Internal Medicine and Nephrology, and his research focuses on the role of TGF-Beta/BMP signaling pathways.He is also the co-founder of FerruMax Pharmaceuticals, Inc., which is a clinical stage company developing a new treatment for anemia.

Dr. Bonventre is the Robert H. Ebert Professor of Medicine at Harvard Medical School and Professor of Health Sciences and Technology at MIT. He is Director of the Renal Division of the Brigham and Women’s Hospital. His research focuses primarily on the study of kidney injury and repair and signal transduction, with a special emphasis on the role of inflammation, biomarkers and stem cells. He also currently Chairs the Kidney Group of the Harvard Stem Cell Initiative and is co-chair of the Stem Cell, Regenerative Medicine and Tissue Engineering Center of the Brigham and Women’s Hospital Research Institute and co-chair of the Technology in Medicine initiative at Brigham and Women’s, and in 2010-11 served as President of the American Society of Nephrology.

Dr. Doogan is currently CEO of Portage Biotech, Inc, and a partner with Mediqventures, LTD. His career spans over 30 years in both major pharma and biotech, including roles of Senior Vice-President and Head of Worldwide Development at Pfizer, CMO and acting CEO of Amarin, and CMO of Prometheus Laboratories.

Dr. Deans is currently the Chief Scientific Officer of Rubius Therapeutics. He has more than 25 years of experience in adult stem cell therapeutics which includes work with stem cells from bone marrow including both hematopoietic as well as mesenchymal stem cell populations. He previously served as the executive vice president at Athersys, Inc., vice president of research at Osiris Therapeutics, and director of research and development at Baxter Healthcare.

Dr. Doogan is currently CEO of Portage Biotech, Inc, and a partner with Mediqventures, LTD. His career spans over 30 years in both major pharma and biotech, including roles of Senior Vice-President and Head of Worldwide Development at Pfizer, CMO and acting CEO of Amarin, and CMO of Prometheus Laboratories.